Valeria Caso: Could Factor XI Inhibition Prevent Recurrent Stroke
Valeria Caso, Chief of Neurology-Stroke Unit at Saronno Hospital, reposted from PACE-CME: Physicians’ Academy for Cardiovascular Education’s on LinkedIn:
“At the ESC Congress, we will discuss the potential role of Factor XI/XIa inhibition in preventing non-cardioembolic stroke.
Why should cardiologists be interested?
Non-cardioembolic stroke is not a single disease.
It includes large-artery atherosclerosis, small-vessel disease, aortic and other vascular sources—and often coexists with coronary and peripheral artery disease.
Despite antiplatelet therapy and intensive vascular risk-factor control, substantial residual ischemic risk remains.
Yet intensifying conventional antithrombotic therapy comes at the cost of more bleeding.
Factor XI inhibition proposes a different strategy: target pathological thrombosis while preserving physiological haemostasis as much as possible.
The central question is therefore not simply whether FXI inhibitors cause less bleeding, but whether they can deliver sufficient protection from ischemic stroke.
At ESC, we will explore:
- why Factor XI may be relevant beyond atrial fibrillation
- which non-cardioembolic stroke mechanisms could benefit
- what previous trials have taught us about efficacy and safety
- why molecules, targets, doses, and degrees of inhibition are not interchangeable
- how cardiologists and neurologists can jointly identify the right patients
The future may not be more anticoagulation—it may be more precise modulation of thrombosis.”
PACE-CME: Physicians’ Academy for Cardiovascular Education shared a post on LinkedIn:
“Recurrent ischemic events remain a challenge after stroke despite current therapy.
At ESC 2026, expert faculty examine phase 3 OCEANIC-STROKE data and the rationale for FXIa inhibition in secondary stroke prevention.
Register and Stay Informed.”
Stay updated with Hemostasis Today.
-
Oct 20, 2026, 06:45Grant Garcia: Why Does a Blood Clot Diagnosis Immediately End an Athlete’s Season?
-
Oct 20, 2026, 06:35Parag Tamhankar: Landmark Study Reveals Genetic Spectrum and Targeted Therapies for ALPS in the Indian Population
-
Oct 20, 2026, 06:26Nina Houben: Neonatal Blood Transfusion Symposium and PhD Defense
-
Oct 20, 2026, 05:46Jan T. Kielstein: DNP Poisoning and Hemoadsorption The Limits of Rescue Therapy
-
Oct 20, 2026, 05:33Giulia Di Paolo: Connecting Plasma Donation to the Patients Who Depend on It
-
Oct 20, 2026, 05:20James Knowles: Exploring Plasma Manufacturing and Strengthening Industry Collaboration
-
Oct 20, 2026, 05:11Giuseppe Lippi։ Understanding Liver Test Abnormalities After AAV Gene Therapy
-
Oct 20, 2026, 05:02Sanam Loghavi: Test Your Hematology Knowledge at ASH 2026!
-
Oct 20, 2026, 04:13Ifeanyichukwu Ifechidere: DOACs Are Not the Answer to Every Anticoagulation Question